Bioverge

Early Stage

Fusing sci-fi with fintech through a health + tech investment platform

Overview

Raised to Date: Raised: $70,724

Total Commitments ($USD)

Platform

Republic

Start Date

05/12/2023

Close Date

08/07/2023

Min. Goal
$25,000
Max. Goal
$1,235,000
Min. Investment

$100

Security Type

SAFE

Series

Seed

SEC Filing Type

RegCF    Open SEC Filing

Valuation Cap

$25,000,000

Discount

0%

Rolling Commitments ($USD)

Status

Active

Reporting Date

06/10/2023

Days Remaining

58

% of Min. Goal

283%

% of Max. Goal

6%

Likelihood of Max
unlikely
Avg. Daily Raise

$2,439

# of Investors

7

Momentum
hot.svg
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2017

Industry

Financial & Insurance Products & Services

Tech Sector

Fintech

Distribution Model

B2B/B2C

Margin

High

Capital Intensity

Low

Location

San Francisco, California

Business Type

Growth

Bioverge, with a valuation of $25 million, is raising funds on Republic. The company has developed a health technology investment platform to merge sci-fi with fintech. The platform is democratizing investing in curated healthcare technology startups with its portfolio of 37 companies with a value of over $3 billion. Bioverge offers a variety of investment options, including deal-by-deal investments, Bioverge Access funds, and thematic funds. Neil Littman and Rick Gibb founded Bioverge in August 2017. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $1.24 million. The campaign proceeds will be used for product development, sales and marketing, new hires, and working capital.

Summary Profit and Loss Statement

FY 2022 FY 2021

Revenue

$247,786

$251,720

COGS

$49,972

$26,101

Tax

$0

$0

 

 

Net Income

$-406,203

$-591,903

Summary Balance Sheet

FY 2022 FY 2021

Cash

$324,314

$487,668

Accounts Receivable

$0

$0

Total Assets

$567,769

$751,759

Short-Term Debt

$52,668

$178,120

Long-Term Debt

$0

$0

Total Liabilities

$52,668

$178,120

Financials as of: 05/12/2023
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Bioverge 08/07/2023 Republic $25,000,000 $70,724 SAFE Active RegCF
Bioverge 02/28/2022 Netcapital $10,014,900 $710,266 Equity - Common Funded RegCF
Bioverge 05/13/2021 Netcapital $10,014,900 $0 Equity - Common Funded Test the Waters / RegCF
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.

Create your first portfolio

Create your own startup investment portfolio on KingsCrowd.

Track all of your startup investments in one place using our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Bioverge on Republic 2023
Platform: Republic
Security Type: SAFE
Valuation: $25,000,000

Follow company

Follow Bioverge on Republic 2023

Buy Bioverge's Deal Report

Bioverge Deal Report

Get KingsCrowd’s comprehensive report on Bioverge including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Bioverge is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Bioverge deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge Pro